News
  • Long-term injectable tetra-PEG@PEG-ALN hydrogel for osteoporosis
    Long-term injectable [email protected] hydrogel for osteoporosis March 29,2021.
    Osteoporosis is defined as a systemic and metabolic bone disease, which is characterized by a decrease in bone mass per unit volume and deterioration of the microstructure of bone tissue, thereby increasing bone fragility and susceptibility to fracture. With the increase in the proportion of elderly populations in the world, and in consequence the number of postmenopausal woman, sarcopenia and osteoporosis are important public health issues. Alendronate (ALN) is a kind of bisphosphonate, which is the most widely used medication in the treatment of skeletal disorders such as osteoporosis, due to its significant pharmacological effect of inhibition on bone resorption. However, the poor permeability exhibit extremely low bioavailability after oral administration (less than 1%). Furthermore, to avoid serious side effects caused by drug-food interactions, patients were instructed to take the medication orally in the morning at least 30 min before breakfast with abundant water and on an empty stomach after an overnight fast, and to remain upright for at least 30 min after dosing. To overcome the limitations of conventional treatments and provide better patient compliance, researchers from the Chinese Academy of Sciences and Zhengzhou University have jointly developed a minimally invasive procedures system for long-term injectable drug delivery, which is effective for clinical osteoporosis therapy (Scheme 1). They introduced PEGylated ALN (PEG-ALN) prodrug into the tetra-PEG hydrogel network, which limits the release rate of ALN because the PEG-ALN polymer does not move easily and freely in the 4 arm PEG hydrogel network, thus achieving slow drug release and local drug delivery, avoiding the serious side effects of systemic administration.
    View More
  • Discussion on Covid-19 Vaccine Excipients
    Discussion on Covid-19 Vaccine Excipients February 26,2021.
    Both frontrunner companies, Moderna and Pfizer-BioNTech, encapsulated their mRNA vaccines using lipid nanoparticles (LNPs) to protect the mRNA from nuclease degradation. LNPs is one of the most advanced delivery systems and has proven to be safe and effective in siRNA delivery. LNP formulations are typically composed of an ionizable lipid, cholesterol, lipid conjugated with polyethylene glycol (PEGylated lipid) and a helper lipid, have recently been recognized as a novel delivery system, and the use of PEG enhances the stability and longevity of the lipid nanoparticles. The mechanism of LNP-mediated delivery of mRNA is not fully understood, but LNPs are suggested to be internalized by endocytosis and are attached electrostatically and fused with the cell membrane via inverted non-bilayer lipid phases. Interestingly, LNPs can also be excreted out of cells by exocytosis,which is a point to note for mRNA delivery via LNPs. Systemically delivered mRNA-LNP complexes mainly target the liver owing to binding of apolipoprotein E and subsequent receptor-mediated uptake by hepatocytes. These microscopic oil-like droplets, approximately 0.1 μm in diameter, surround and protect the fragile mRNA during production, transport, and eventual injection into the body. On the other hand, nanoparticles as vaccine delivery systems can enhance antigen delivery to the target tissue and cell populations of interest, and act as immunostimulatory adjuvants to activate or augment specific immune responses. PEG has never been found in any other vaccine in the world, and this will be another new use of PEG in the pharmaceutical field. SINOPEG is Covid-19 Vaccine Excipients supplier.  research use only
    View More
  • Happy Spring Festival!
    Happy Spring Festival! February 19,2021.
    The Chinese New Year has passed, and SINOPEG hopes to reach cooperation with you in the new year!
    View More
first page 1 2 3 4 5 6 7 last page

A total of 7 pages

Copyright © XIAMEN SINOPEG BIOTECH CO., LTD. All Rights Reserved.

Home

Products

News

contact